Amgen (AMGN) Tops Q4 EPS by 12c, Offers Guidance

Amgen (NASDAQ: AMGN) reported Q4 EPS of $4.71, $0.12 better than the analyst estimate of $4.59. Revenue for the quarter came in at $8.2 billion versus the consensus estimate of $8.12 billion.

GUIDANCE:

Amgen sees FY2024 EPS of $18.90-$20.30, versus the consensus of $19.83. Amgen sees FY2024 revenue of $32.4-33.8 million, versus the consensus of $32.5 million.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Amgen (AMGN) PT Lowered to $430 at UBS
• Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh